sgp130 in Chronic Human Liver Disease

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT00770198
First received: October 8, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.


Condition
Alcoholic Liver Disease
Chronic Hepatitis C Virus Infection

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of IL-6 Transsignaling in Chronic Human Liver Disease

Resource links provided by NLM:


Further study details as provided by Erasme University Hospital:

Biospecimen Retention:   Samples Without DNA

plasma, liver biopsies, and peripheral blood mononuclear cell culture medium.


Enrollment: 129
Study Start Date: January 2005
Study Completion Date: October 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
alcoholic liver disease
alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
chronic HCV hepatitis
chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution

Detailed Description:

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients of Erasme University Hospital

Criteria

Inclusion Criteria:

  • Alcohol excess intake and suspected liver disease
  • Alcohol excess intake and clinical liver cirrhosis
  • chronic hepatitis C virus infection and suspected liver disease
  • chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria:

  • other (superimposed) liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770198

Locations
Belgium
Hopital Erasme - Dpt of Gastroenterology
Brussels, Belgium, 1070
Sponsors and Collaborators
Erasme University Hospital
Investigators
Principal Investigator: Arnaud Lemmers, MD Erasme Hospital, Gastroenterology Dpt
  More Information

No publications provided

Responsible Party: Olivier Le Moine, MD, PhD, Erasme University Hospital
ClinicalTrials.gov Identifier: NCT00770198     History of Changes
Other Study ID Numbers: AL-gp130
Study First Received: October 8, 2008
Last Updated: October 8, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by Erasme University Hospital:
liver
alcohol
HCV

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis C
Liver Diseases
Liver Diseases, Alcoholic
Virus Diseases
Hepatitis C, Chronic
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on July 24, 2014